INDV N Stock Overview
Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for INDV N from our risk checks.
Indivior PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£314.49 |
| 52 Week High | UK£0 |
| 52 Week Low | UK£0 |
| Beta | -0.17 |
| 11 Month Change | -51.30% |
| 3 Month Change | -51.30% |
| 1 Year Change | -51.30% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| INDV N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | -51.3% | -1.3% | -0.3% |
| 1Y | -51.3% | -19.3% | -4.0% |
Return vs Industry: INDV N underperformed the MX Pharmaceuticals industry which returned -15% over the past year.
Return vs Market: INDV N underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| INDV N volatility | |
|---|---|
| INDV N Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: INDV N's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine INDV N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 900 | Mark Crossley | www.indivior.com |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company’s product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex.
Indivior PLC Fundamentals Summary
| INDV N fundamental statistics | |
|---|---|
| Market cap | Mex$42.64b |
| Earnings (TTM) | Mex$3.03b |
| Revenue (TTM) | Mex$16.73b |
14.1x
P/E Ratio2.5x
P/S RatioIs INDV N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDV N income statement (TTM) | |
|---|---|
| Revenue | US$838.00m |
| Cost of Revenue | US$140.00m |
| Gross Profit | US$698.00m |
| Other Expenses | US$546.00m |
| Earnings | US$152.00m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 27, 2022
| Earnings per share (EPS) | 1.10 |
| Gross Margin | 83.29% |
| Net Profit Margin | 18.14% |
| Debt/Equity Ratio | 104.3% |
How did INDV N perform over the long term?
See historical performance and comparison